Like Peptide-1 Receptor (GLP-1R) Agonists in Type 2 Diabetes and Obesity: 68-Market Analysis and Sales Forecast" report has been added to ResearchAndMarkets.com's offering.Across the 68 markets, sales ...

Tirzepatide is just as effective in reducing cardiovascular risk driven by central adiposity as that driven by general ...

Treatment for OUD is currently dominated by opioid agonist therapies that are highly regulated due to their liability for ...

A study conducted using electronic health record data from a collective of U.S. health care systems found that most adults ...

Scientists have discovered an antibody treatment that may help prevent both muscle loss and bone density loss in people using ...

ORLANDO, FLA. — Increasing levels of protein and fiber, stressing portion control, and adding savory flavors are ways that ...

Many patients with overweight or obesity discontinue glucagon-like peptide-1 (GLP-1) receptor agonist therapy within o ...

Weight-inclusive health care is the provision of equitable care without perpetuating weight stigma among patients of all body ...

BIRMINGHAM, Ala. (WBRC) - Glucagon-like peptide-1 (GLP-1) is a well-known medication used by physicians to treat Type 2 diabetes. GLP-1 has also become popular when used as a weight loss drug. But, ...

UK: A recent consensus statement from leading UK medical organizations—including the Association of Anaesthetists, the ...

Researchers had found in a new study that sodium-glucose cotransporter-2 inhibitors (SGLT-2is) and glucagon-like peptide-1 ...